Expression of the endothelial cell differentiation gene 7 (EDG-7), a lysophosphatidic acid receptor, in ovarian tumor

Journal of Obstetrics and Gynaecology Research

Volumn 31, Issue 4, 2005, Pages 344-351

  Nakamoto, Tsuyoshi ^a   Yasuda, Katsuhiko ^a   Yasuhara, Masahiro ^a   Yoshimura, Tomoo ^a   Kinoshita, Teruki ^a   Nakajima, Tatsuya ^a   Okada, Hidetaka ^a   Ikuta, Akiko ^a   Kanzaki, Hideharu ^a  

^a KANSAI MEDICAL UNIVERSITY   (Japan)

Author keywords

EDG 7; Endothelial cell differentiation gene; G protein coupled receptor; Lysophosphatidic acid; Ovarian cancer

Indexed keywords

DEOXYRIBONUCLEASE I; G PROTEIN COUPLED RECEPTOR; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; LYSOPHOSPHATIDIC ACID; LYSOPHOSPHATIDIC ACID RECEPTOR; MESSENGER RNA; MITOGENIC AGENT; PROTEIN EDG 7; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CELL DIFFERENTIATION; CELL PROLIFERATION; CLEAR CELL CARCINOMA; CONTROLLED STUDY; CYSTADENOCARCINOMA; EDG 7 GENE; ENDOMETRIOID CARCINOMA; ENDOTHELIUM CELL; FEMALE; GENE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; NORTHERN BLOTTING; OVARY TUMOR; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TERATOMA;

CASE-CONTROL STUDIES; CELL LINE, TUMOR; CYSTADENOCARCINOMA, MUCINOUS; CYSTADENOCARCINOMA, SEROUS; DNA PRIMERS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; OVARIAN NEOPLASMS; RECEPTORS, LYSOPHOSPHATIDIC ACID; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 23944492843     PISSN: 13418076     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2005.00299.x     Document Type: Article

References (36)

1. Statistics and Information Department, Minister's Secretariat. Vital Statistics of Japan, vol. 3. Tokyo: Ministry of Health, Labour and Welfare, 2002.
2. Richardson GS, Scully RE, Nikrui N, Nelson JH. Common epithelial cancer of the ovary (first of two parts). N Engl J Med 1985; 312: 415-424.
3. Richardson GS, Scully RE, Nikrui N, Nelson JH. Common epithelial cancer of the ovary (second of two parts). N Engl J Med, 1985; 312: 474-483.
4. Auerspreg N, Edelson MI, Mok SC, Johnson SW, Hamilton TC. The biology of ovarian cancer. Semin Oncol 1998; 25: 281-204.
5. Mills GB, May C, McGill M, Roifman M, Mellors A. Ascitic fluid from ovarian cancer patients contains a putative new growth factor: Identification, characterization and mechanism of action. Cancer Res 1998; 48: 1066-1071.
6. Westermann AM, Beijnen JH, Moolenaar WH, Rodenhuis S. Growth factors in human ovarian cancer. Cancer Treat Rev 1997; 23: 113-131.
7. Yasui T, Uemura H, Irahara M, Aono T. Effects of transforming growth factor-β on the production of parathyroid hormone-related peptide in a human ovarian cancer cell line in vitro. J Obstet Gynecol Res 1997; 23: 231-238.
8. Berchuck A, Carney M. Human ovarian cancer of the surface epithelium. Biochem Pharmacol 1997; 54: 541-544.
9. Bookman MA. Biological therapy of ovarian cancer: Current directions. Semin Oncol 1998; 25: 381-396.
10. Xu Y, Fang XJ, Casey G, Mills GB. Lysophospholipids activate ovarian and breast cancer cells. Biochem J 1995; 309: 933-940.
11. Xu Y, Gaudette DC, Boynton J et al. Characterization of an ovarian cancer activating factor in ascites from ovarian cancer patients. Clin Cancer Res 1995; 1: 1223-1232.
12. Eichholtz T, Jalink K, Fahrenfort I, Moolenaar WH. The bioactive phospholipid lysophosphatidic acid is released from activated platelets. Biochem J 1993; 291: 677-680.
13. Sugiura T, Nakane S, Kishimoto S, Waku K, Yoshioka Y, Tokumura A. Lysophosphatidic acid, a growth factor-like lipid, in the saliva. J Lipid Res 2002; 43: 2049-2055.
14. Tokumura A, Miyake M, Nishioka Y, Yamano S, Aono T, Fukuzawa K. Production of lysophosphatidic acids by lysophospholipase D in human follicular fluids of in vitro fertilization patients. Biol Reprod 1999; 61: 195-199.
15. Nakane S, Tokumura A, Waku K, Sugiura T. Hen egg yolk and white contain high amounts of lysophosphatidic acids, growth factor-like lipids: Distinct molecular species compositions. Lipids 2001; 36: 413-419.
16. Hama K, Bandoh K, Kakehi Y, Aoki J, Arai H. Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: Possible role of LPA-binding proteins in activation of LPA receptors. FEBS Lett 2002; 523: 187-192.
17. Moolenaar WH, Kranenburg O, Postma FR, Zondag GC. Lysophosphatidic acid: G-protein signaling and cellular responses. Curr Opin Cell Biol 1997; 9: 168-173.
18. Moolenaar WH. Lysophosphatidic acid, a multifunctional phospholipid messenger. J Biol Chem 1995; 270: 12949-12952.
19. Hecht JH, Weiner JA, Post SR, Chun J. Ventricular zone gene-1 (vzg-1) encodes a lysophosphatidic acid receptor expressed in neurogenic regions of the developing cerebral cortex. J Cell Biol 1996; 135: 1071-1083.
20. An S, Bleu T, Hallmark OG, Goetzl EJ. Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid. J Biol Chem 1998; 273: 7906-7910.
21. Bandoh K, Aoki J, Hosono H et al. Molecular cloning and characterization of a novel human G protein-coupled receptor, EDG-7, for lysophosphatidic acid. J Biol Chem 1999; 274: 27776-27785.
22. Ishii I, Contos JJA, Fukushima N, Chun J. Functional comparisons of the lysophosphatidic acid receptors, LPA1/VZV-1/EDG-2, LPA2/EDG-4, and LPA3/EDG-7 in neuronal cell lines using a retrovirus expression system. Mol Pharmacol 2000; 58: 895-802.
23. An S, Bleu T, Zheng Y, Goetzl EJ. Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization. Mol Pharmacol 1998; 54: 881-888.
24. Xu Y, Shen Z, Wiper DW et al. Lysophosphatidic acid as a potential biomarker for ovarian and other gynecologic cancers. JAMA 1998; 280: 719-723.
25. Fang X, Schummer M, Mao M et al. Lysophosphatidic acid is a bioactive mediator in ovarian cancer. Biochim Biophys Acta 2002; 1582: 257-264.
26. Benedet JL, Hacker NF, Ngan HYS. Staging Classifications and Clinical Practice Guide Lines of Gynaecologic Cancers, 2nd edn. London: FIGO Committee on Gynecologic Oncology and IGCS Guidelines Committee, 2003.
27. Ercolani L, Florence B, Denaro M, Alexander M. Isolation and complete sequence of a functional human glyceraldehyde-3-phosphate dehydrogenase gene. J Biol Chem 1988; 263: 15335-15341.
28. Shuman S. Novel approach to molecular cloning and polynucleotide synthesis using vaccinia DNA topoisomerase. J Biol Chem 1994; 269: 32678-32684.
29. Sanger F, Nicklen S, Coulson AR. DNA sequencing with chain-terminating inhibitors. Proc Natl Acad Sci USA 1977; 74: 5463-5467.
30. Hatayama H, Kanzaki H, Iwai M et al. Progesterone enhances macrophage colony-stimulating factor production in human endometrial stromal cells in vitro. Endocrinology 1994; 135: 1921-1927.
31. Vincent S, Marty L, Fort P. S26 ribosomal protein RNA: An invariant control for gene regulation experiments in eucaryotic cells and tissues. Nucleic Acids Res 1993; 21: 1498.
32. Hu YL, Albanese C, Pestell RG, Jaffe RB. Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells. J Natl Cancer Inst 2003; 95: 733-740.
33. Pestell RG, Albanese C, Reutens AT, Segall JE, Lee RJ, Arnold A. The cyclins and cyclin-dependent kinase inhibitors in hormonal regulation of proliferation and differentiation. Endocr Rev 1999; 20: 501-534.
34. Worsley SD, Ponder BA, Davies BR. Overexpression of cyclin D1 in epithelial ovarian cancers. Gynecol Oncol 1997; 64: 189-195.
35. Hu YL, Tee MK, Goetzl EJ et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst 2001; 93: 762-768.
36. Bandoh K, Aoki J, Taira A, Tsujimoto M, Arai H, Inoue K. Lysophosphatidic acid (LPA) receptors of EDG family are differentially activated by LPA species. FEBS Lett 2000; 478: 159-165.